News
"Pharmaceuticals will be tariffed probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to ...
Tiny $35M Biotech Leverages Proven Technology to Potentially Revolutionize How Diabetes and Obesity Medications Are Delivered (NASDAQ:PYPD)PolyPid ...
For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...
Lilly Endowment Community Scholarship application is now available in Carroll County through the. The Lilly Endowment Community Scholarship Program (LECSP) will provide 147 scholarships ...
A new multi-million dollar grant from the Eli Lilly and Company Foundation will help support a new initiative that aims to increase STEM engagement, achievement and career ...
Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.
INDIANAPOLIS — Indianapolis Public Schools (IPS) just received a major grant from the Eli Lilly and Company Foundation to help increase STEM readiness among students. The $5.5 million grant will help ...
The IPS Foundation has received a $5.5 million grant from the Eli Lilly Foundation to support Destination 2032, a new initiative aimed at enhancing STEM education for IPS students.
Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results